Share this article
Share this article
NEW YORK, July 01, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ( Provention or the Company ) (NASDAQ: PRVB) and certain of its officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 21-cv-11613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Provention securities between November 2, 2020 and April 8, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Message :
Required fields
NEW YORK, July 1, 2021 /PRNewswire/ Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Western District of Washington on behalf of investors that purchased Athira Pharma, Inc. ( Athira or
the Company ) (NASDAQ: ATHA) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the Registration Statement ) issued in connection with the Company s September 2020 initial public offering ( IPO or the Offering ) at $17.00 share.
All investors who purchased
and incurred losses are urged to contact the firm immediately at classmember@whafh.com
Share this article
Share this article
NEW YORK, July 1, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Rekor Systems, Inc. f/k/a Novume Solutions, Inc. ( Rekor or the Company ) (NASDAQ: REKR) ; (NVMM) and certain of its officers. The class action, filed in the United States District Court for the District of Maryland, Northern Division, and docketed under 21-cv-01604, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Rekor securities between April 12, 2019 and May 25, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Share this article
Share this article
NEW YORK, July 1, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Frequency Therapeutics, Inc. ( Frequency or the Company ) (NASDAQ: FREQ) and certain of its officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 21-cv-11040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Frequency s common stock between November 16, 2020 and March 22, 2021, inclusive (the Class Period ), seeking to pursue remedies under the Securities Exchange Act of 1934 (the Exchange Act ). This action brings claims against Defendants Frequency and the Company s Chief Executive Officer ( CEO ), David L. Lucchino ( Lucchino ), and seeks to recover damages caused by Defendants violations of the Exchange Act.
Mark Alan Deakins Indicted For Sexual Exploitation Of Children; FBI Seeks Additional Victims Friday, July 2, 2021
The Federal Bureau of Investigation is asking for the public’s help in identifying potential historical victims of convicted sexual offender Mark Alan Deakins who were victimized, photographed, and/or filmed/videoed by Deakins from the 1990s through June, 2021.
It is believed there could be more than 20 victims throughout the Southeast.
On June 16, a federal grand jury in Knoxville returned a one count indictment against Mark Alan Deakins, 61, of Chattanooga, for the sexual exploitation of a child. Deakins is currently being held pending trial in United States District Court, in Chattanooga.